{
  "abstract": "Circulating tumour DNA (ctDNA) offers a minimally invasive approach for early detection of cancer, monitoring molecular residual disease, assessing molecular response and identifying treatment resistance in advanced stages. Additionally, ctDNA enhances clinical decision-making by enabling real-time tumour assessment. This review highlights the growing role of liquid biopsy as a predictive and prognostic tool in non-small cell lung cancer management.",
  "authors": [
    {
      "affiliations": [
        "Medical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"
      ],
      "name": "Beatriz Jimenez-Munarriz"
    },
    {
      "affiliations": [
        "Medical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"
      ],
      "name": "Berenice Urtecho"
    },
    {
      "affiliations": [
        "Medical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"
      ],
      "name": "Mary R Rabey"
    },
    {
      "affiliations": [
        "Medical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada"
      ],
      "name": "Natasha B Leighl"
    }
  ],
  "title": "Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection",
  "uid": "cec05054-6d87-5bfd-b954-1a48ca819ca1"
}